Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Press release: The first results from the Ebola vaccine trial carried out by the Jenner Institute found that the vaccine has an acceptable safety profile at the doses tested, and is able to generate an immune response. The paper published in the New England Journal of Medicine reports safety data and immune responses for the volunteers for 28 days after immunisation.